Using cell-derived particles to deliver therapeutic molecules
Official title: Leveraging cell-derived bioparticles for macromolecular delivery
Funded at Whitehead Institute for Biomedical Res · NIH-10921628 · Data updated 2026-11-12
This study is exploring new ways to help deliver important treatments like proteins and RNAs into cells, which could lead to better and safer therapies for different diseases by improving how we produce tiny particles that carry these treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Whitehead Institute for Biomedical Res NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 18, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $487,500 |
| NIH project number | 1DP5OD037342-01 |
| Project ID | NIH-10921628 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with conditions that could benefit from advanced macromolecular therapies, such as genetic disorders or cancers.
✕Less likely to help
Patients who do not have conditions that require macromolecular therapies may not benefit from this research.
What this research studies
This research focuses on developing innovative methods to deliver macromolecules, such as proteins and RNAs, into cells to treat diseases. It aims to enhance the production of cell-derived bioparticles, which are promising vehicles for delivering these therapeutic agents. By manipulating specific genes in the cells that produce these bioparticles, the researchers hope to improve the efficiency of their production. This approach could lead to safer and more effective treatments for various conditions.
Why it matters
Potential benefit: If successful, this research could significantly improve the delivery of therapeutic macromolecules, leading to better treatment outcomes for patients with various diseases.
How similar studies have gone: Previous research has shown promise in using cell-derived bioparticles for drug delivery, indicating that this approach has potential for success.
Where this research is happening
-
Whitehead Institute for Biomedical Res
Cambridge, United States Active
Researchers
- Principal investigator: Raguram, Aditya — Whitehead Institute for Biomedical Res
- Study coordinator: Raguram, Aditya
Related research
Other NIH-funded projects on the same topics.
-
Illuminating the dark proteome to fight cancer
A research program aims to map and understand mysterious dark proteome proteins in cancer and to develop pre-clinical therapies that target them.
-
Center for Genome Editing and Recording: Next-Generation Genome and Epigenome Tools for Disease
A research center is developing ultra-precise genome and epigenome editing tools to better understand and treat human diseases, with a focus on how genetic variants influence disease and how to safely modify them.
-
Understanding how polyamines work in human cells (a potential cancer focus)
Researchers are studying how small molecules called polyamines help cancer-related cell growth and survival, with new ways to measure them inside living cells.
-
Delivering therapeutic macromolecules with cell-derived bioparticles
A researcher aims to safely and efficiently deliver big therapeutic molecules into human cells using cell-derived bioparticles to help treat diseases.
-
Stem cell and regeneration rules in planarians
Researchers study how planarians regulate stem cells to regrow body parts, hoping to reveal ideas that could someday help human tissue repair.
-
Post-transcriptional gene regulation in human cells
A grant studying how microRNAs control which genes are turned on or off in human cells, with a focus on cancer and development.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.